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TREATMENT OF BENIGN PROSTATIC HYPERTROPHY
             WITH ALLYLESTRENOL
Hidenori TAKAyAMA， Kiyoshi OsHiRo and Tadashi HAyAsHi
  From the DePartment of Urology， Kurashiki Central HosPital， Okayama
            r（］hief：H。 Taた4γama，ルf．エ）．ノ
  Fifteen patients with BPH received a progestational agent， allylestrenol （Gestanon） daily for
periods ranging to at least 3 months or more． ．
  Dysuria， being complained by 12 patients， was judged to have disappeared in 8 patients， lessened
in 2 and’remained unchanged’in 2． ’ Of 11 patients with complaint of frequent urination， 6 patients
returned to normal frequency and 3 showed 4 decrease of frequency．
  Residual urine volumes decreased in 13 of 15 patients beginning one to two months after start
of therapy and increased in 2．
  Reduction in size of the prostate as measured by the cystourethrogram was seen in 5 of 1 1 patients．
But in all the patients， no remarkable change in size of the gland was noted under rectal examination．
  Biopsy specimen for’ histological examination was successfully obtained before and after allyl一 ．
estrenol administration in 4 patients． Flattening of epithelia．1 projection into the lumen， dilatation
of acini and decrease in epithelial cell heights were demonstrated in 2 of 4 patients．
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Gestanon 1錠にはallylestrenol 5 mgを含有してい
る．
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Table 2． Residual urine （ml） before
     therapy．
and aft r
No．Before1 2 3 4 5 6 7 8 9 ゆM
1 54028 i3． 11 161．5 IO12 5 6 8
2 3815i8 5
層3 70020182514 12 5
4 3 5 7 4 8 4 3
5 12 15 5 6 8 7
6 90io5lOO！40IOO
7 15 10 i．5 2 3 4 3 2
8 903Q lO 4 O
9 21012 6 3
lO 7 6 4 5
1．1 20151810
12 6005150380500
｝3 5 3 3 4 O
i．4 7050322210












































Table 3． Evaluation of effects for dysurii and
     frequent urination and shortest time in
     weeks of medication which show impro－
     vement in clinical sy皿ptoms．
No DysuriaFrequenturination
ebiore 1 2 3 4 5 6 7 89 la M
Fig． 1． Changes of residual urine volume before












2 none 5Wnone 6W
5 improved9Wimpro＞ed｝OW




8 none 5Wnone 5W






























Table 4． Relationship between residual urine vol－
     ume and duration of therapy．
Tme in month whlch 1 Time in month which
Po†ien†
mo．












































lable 3．unan．aes ol prostatlc mass ln cystouretn－
rogram．
Po刊en Before Af十er
No． H V M 、卜｛ 〉 M
cm cmcm cm cm cm54 刀 62552， 64 58
2 6．7 47 57 6．8 49 585
3 Z2 76 74 64 72 68
4 6」 5．o 5556．○ 53 565
5 6．4 5．4 5．9 6」 49 55
7 48 5β 52 4．6 5．6 5，【
8・ 5．2 5．O 5」 5．2 5．｝ 5．15
9 6．O 6．1 6D56．1 6．3 6．2
日 5．7 6．○ 5．8558 60 5．9
15 6．9 73 7．1 72 77 745
15 7．1 5．2 6」5 5．6 4．8 52
H means horizontal diameter in prostatic



















Before administration of allylestrenol． A｛ter the administration． Urethrogram shows a reduction of pro－
                                               static inass in both of horizontal and vertical diameter．
























Before administration of allyle3trenol．








Biopsy framsent showing Photograph of prostatic gland epithelial cells following allylestrenol
                therapy． Flattening of epjthelial projections into lumen， dilatation
                of acini and decrease in epithelial cell heights are shown．
1．ight皿icroscopic photograph of the prostate （case No・ 1）・
・x・
   綴
．蹄秘
  畝露






Aft r the administration．
Fig． 4 are seen．
Fig． 5． Light micrograph of the prostate （case No． 10）．
，気；：要離趣’

































































 肝機能では（Table 7）， GOT， GPTに関しては症
例No．7を除く全例に投与前後に異常を認めないが，
Table 6
RBC  （XIO4） WB．C 附      〔％）




















































































































































































































































































































































































dl， No． 3：21 mg／dl， No． 5：28 mg／dl， No． 6：33 mgf
dl， No．7：22 mg／dl）であるが，投与後はこのうち2
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